1. Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel). 2021;9(3):243. doi:10.3390/vaccines9030243
2. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. MedRxiv. 2021. doi: 10.1101/2021.05.22.21257658
3. Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021. 25: 244. doi: 10.1186/s13054-021-03662-x
4. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. BioXriv. 2021. doi: 10.1101/2021.05.08.443253
5. World Health Organization. Episode #45-Delta Variant. Tersedia di: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-45---delta-variant?gclid=Cj0KCQjwub-HBhCyARIsAPctr7zXSzaEOgnp3Yc2T_T-5f3cPSpxPzt1OB1-y14V5zb0pzxnA8-xCOEaAs-JEALw_wcB
6. Vaidyanathan G. Coronavirus variants are spreading in India — what scientists know so far. 2021. Nature. 593;321-322. doi: 10.1038/d41586-021-01274-7
7. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, Flowers MW, Hussaini L, Ciric CR, Bechnack S, Stephens K, Mokhtari EB, Mudvari P, Creanga A, Pegu A, Derrien-Colemyn A, Henry AR, Gagne M, Graham BS, Wrammert J, Douek DC, Boritz E, Pinsky BA, Suthar MS. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. N Engl J Med. 2021. doi: 10.1056/NEJMc2107799
8. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, Pullukçu H, Batum Ö, Şimşek Yavuz S, Turhan Ö, Yıldırmak MT, Köksal İ, Taşova Y, Korten V, Yılmaz G, Çelen MK, Altın S, Çelik İ, Bayındır Y, Karaoğlan İ, Yılmaz A, Özkul A, Gür H, Unal S; CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021. 398; 213-222. doi: 10.1016/S0140-6736(21)01429-X
9. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatziioannou T, Bieniasz PD, Darnell RB. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021. 384(23); 2212-2218. doi: 10.1056/NEJMoa2105000
10. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021. doi: 10.1038/s41586-021-03777-9
11. Davis C, Logan N, Tyson G, Orton R, Harvey W, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. MedXriv. 2021. doi: 10.1101/2021.06.23.21259327
12. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. Tersedia di: https://www.medrxiv.org/content/10.1101/2021.07.10.21260232v2